An exciting moment for our team as we celebrated becoming a public company by ringing the #OpeningBell at @Nasdaq! This marks a new chapter in developing therapies for those living w/ #cancer. Thanks to our hard working & talented team who made this achievement possible. $BCAX

Members of Bicara were proud to attend #ESMO25, where we connected with colleagues, collaborators, and innovators across the #oncology community. Each year, this meeting reinforces the momentum and shared commitment driving new possibilities for people living with #cancer.

We’re thrilled to introduce three new members of our leadership team who bring with them a deep expertise and passion for advancing #oncology innovation. We look forward to the leadership and insight they bring as we advance our mission to transform the lives of people living

We’re pleased to share that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation (BTD) for ficerafusp alfa in combination with pembrolizumab for the treatment of patients with 1L HPV-negative recurrent/metastatic (R/M) head and neck squamous cell

Today is #WorldCancerResearchDay, a reminder of the vital role research plays in transforming #cancer care. At Bicara, we are driven by urgency & dedication to bring forward innovative therapies that put our patients first. Liz shares how she began her career in #oncology & the

Our team is the heart of Bicara. We’re united by a shared commitment to deliver meaningful therapies for people living with #cancer, while creating an environment where everyone can grow, learn, & thrive. By bringing together diverse backgrounds and perspectives, we amplify the

It's officially been one year since $BCAX became a publicly traded company! Over the last year, thanks to the dedication of our team, we’ve made tremendous progress toward our mission to improve the lives of people living with #cancer through the development of innovative

#DYK roughly 80% of R/M #HNSCC cases are HPV-negative, a subtype with significantly worse prognosis compared to HPV-positive disease? HPV-negative #HNSCC is especially difficult, with tumors that often recur locally and life-altering risks including fatal bleeding, severe pain,

Congratulations to our CEO, Claire Mazumdar, on being named a #Fierce50 honoree in the leadership category. This recognition highlights Claire’s visionary leadership at Bicara - driving meaningful change, advancing first-in-class treatments, and inspiring a culture of innovation

Bicara leadership will be attending several investor conferences in September. We look forward to sharing updates on the progress of our lead program, ficerafusp alfa, and our approach to addressing the significant unmet needs for patients with various solid tumors. To access the

Are you or a loved one living with head and neck cancer? The FORTIFI-HN01 trial is a pivotal Phase 2/3 study evaluating a potential new treatment option and is currently enrolling patients. @BicaraTx    https://t.co/re6l1gjdcF   #ClinicalTrial #HeadAndNeckCancer #CancerResearch

With a growing team & exciting progress happening at Bicara, we came together in Boston for two days of connection & alignment - kicking things off with a Red Sox outing & continuing with our company-wide All Hands offsite. We heard from inspiring guest speakers, strengthened

For more info, visit: https://t.co/vKt8AmccfR Ficerafusp alfa is being evaluated in FORTIFI-HN01, a pivotal Phase 2/3 trial with pembrolizumab in 1L R/M #HNSCC. This global, randomized, double-blinded, placebo-controlled study will enroll ~650 patients, excluding HPV+ OPSCC, to

Today, we announced our second quarter 2025 financial results and business update. For more details, read the full press release here: https://t.co/r0uOOHG6Pq

#HNSCC remains one of the leading causes of cancer-related death & disability across the globe, & incidence rates are projected to increase by 30% by 2030. This past Sunday was #WorldHeadAndNeckCancerDay, which serves as a reminder for our shared responsibility to support those

#DYK 1 in 3 kids in MA face clothing insecurity and may lack school-ready essentials? That’s why we teamed up with @LS_Cares & @c2cboston to help by organizing backpacks, clothes, & supplies so local kids can start the school year strong. A powerful reminder that even “simple”

Strong science starts with strong people. Meet Pauline Dufresne, our Chief People Officer, who brings 18 years of HR experience, with the past decade in life sciences, to help scale Bicara with purpose and care. “Bicara’s culture of high integrity, perseverance, and respect

Our CEO Claire Mazumdar joined @ldtimmerman on The Long Run podcast to talk about our bifunctional antibody for patients with HPV-negative HNSCC, how it sets Bicara apart, and what's ahead. Listen below.

Source: Head & Neck Cancer Alliance. (n.d.). Self-Exam Guide. Retrieved June 2, 2025 from

Head & neck cancers account for nearly 4% of all cancers, and if caught early, carry an 80% survival rate, but unfortunately, early diagnosis is still too uncommon. At Bicara, we believe working towards a future where more patients become survivors starts with education &

This June, we recognize the more than 18 million in the U.S. who live with a history of cancer. That number is projected to reach 26 million by 2040. #NationalCancerSurvivorsMonth honors the strength and resilience of those impacted & highlights the importance of continued